Current choice of treatments for neovascular AMD

Kevin Lai, Gennady Landa

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Age-related macular degeneration is the leading cause of irreversible blindness in developed countries with the neovascular form accounting for the majority of severe vision loss in the disease. The management of wet age-related macular degeneration has improved drastically in the past decade as anti-VEGF agents took its place at the forefront of treatment. As the choice of therapy is based on a number of factors, this review summarizes the pivotal studies that brought these agents to use and compares the different agents currently available. This review also briefly describes the promising new therapies that are in development.

Original languageEnglish
Pages (from-to)135-140
Number of pages6
JournalExpert Review of Clinical Pharmacology
Issue number1
StatePublished - 1 Jan 2014


  • Avastin
  • Eylea
  • Lucentis
  • neovascular age-related macular degeneration
  • treatment


Dive into the research topics of 'Current choice of treatments for neovascular AMD'. Together they form a unique fingerprint.

Cite this